Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 1,901–2,000 of 15,747
Zhang, B., Upadhyay, R., Hao, Y., Samanovic, M. I., Herati, R. S., Blair, J. D., Axelrad, J., Mulligan, M. J., Littman, D. R., & Satija, R. (2023) · Nature Immunology · doi:10.1038/s41590-023-01608-9 · Cited by 57
Tailoring the physicochemical properties of nanomaterials for immunomodulation
Deng, J., Wang, J., Shi, J., Li, H., Lu, M., Fan, Z., Gu, Z., & Cheng, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114039 · Cited by 64
Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals
Lingel, H., Meltendorf, S., Billing, U., Thurm, C., Vogel, K., Majer, C., Prätsch, F., Roggenbuck, D., Heuft, H., Hachenberg, T., et al. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102682 · Cited by 59
Chen, X., Luo, D., Mei, B., Du, J., Liu, X., Xie, H., Liu, L., Su, S., & Mai, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.004 · Cited by 59
Tarab‐Ravski, D., Hazan‐Halevy, I., Goldsmith, M., Stotsky‐Oterin, L., Breier, D., Naidu, G. S., Aitha, A., Diesendruck, Y., Ng, B. D., Barsheshet, H., et al. (2023) · Advanced Science · doi:10.1002/advs.202301377 · Cited by 73
Could live attenuated vaccines better control COVID-19?
Okamura, S., & Ebina, H. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.018 · Cited by 70
“, showed 95% efficacy in a phase III clinical trial [22].”
BackgroundAdverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies
Dhamanti, I., Suwantika, A. A., Adlia, A., Yamani, L. N., & Yakub, F. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s400458 · Cited by 62
“Another study conducted worldwide (US, Argentina, Brazil, South Africa, Germany, and Turkey) showed that more than 30% of participants had side effects.(10) Clinical trials conducted in Argentina, Brazil,”
BackgroundThe paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Kant, A. C., Jansen, J. R. G., van Balveren, L., & van Hunsel, F. P. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01151-w · Cited by 59
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 59
Shim, J., Ryu, K., Lee, S. H., Cho, E.-A., Lee, Y. J., & Ahn, J. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126549 · Cited by 56
“The prevention rate of COVID-19 vaccines is over 80 percent, and they are expected to be a game-changer [3,4].”
BackgroundDurability of Heterologous and Homologous COVID-19 Vaccine Boosts
Tan, C. S., Collier, A.-R. Y., Yu, J., Liu, J., Chandrashekar, A., McMahan, K., Jacob-Dolan, C., He, X., Roy, V., Hauser, B. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26335 · Cited by 61
Ongun, M., Lokras, A. G., Baghel, S. S., Shi, Z., Schmidt, S., Franzyk, H., Rades, T., Sebastiani, F., Thakur, A., & Foged, C. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114266 · Cited by 75
“In particular, the mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have demonstrated the remarkable potential of the mRNA vaccine technology in the fight against infectious diseases due to their rapid manufacturability as well as high efficacy and safety [4].”
BackgroundEfficacy of COVID-19 vaccines: From clinical trials to real life
Deplanque, D., & Launay, O. (2021) · Therapies · doi:10.1016/j.therap.2021.05.004 · Cited by 63
“It should be underlined that mRNA vaccines [10, 11] appear to have a higher efficacy than that of adenoviral vectored vaccines [12, 13].”
BackgroundInfluentialVikkurthi, R., Ansari, A., Pai, A. R., Jha, S. N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B. P., Parray, H. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01161-5 · Cited by 63
A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19
Szarpak, L., Rafique, Z., Gąsecka, A., Chirico, F., Gaweł, W., Hernik, J., Kamińska, H., Filipiak, K. J., Jaguszewski, M. J., & Szarpak, Ł. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0072 · Cited by 59
“Several drugs have been proposed which include, but are not limited to: hydroxychloroquine [7, 8], janus kinase 2 inhibitor Fedratinib [9] or Remdesmivir [10].”
BackgroundSalerno, L., Craxì, L., Amodio, E., & Coco, G. L. (2021) · Vaccines · doi:10.3390/vaccines9080927 · Cited by 66
COVID-19 seasonality in temperate countries
D’Amico, F., Marmiere, M., Righetti, B., Scquizzato, T., Zangrillo, A., Puglisi, R., & Landoni, G. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112614 · Cited by 57
Glück, V., Grobecker, S., Tydykov, L., Salzberger, B., Glück, T., Weidlich, T., Bertok, M., Gottwald, C., Wenzel, J. J., Gessner, A., et al. (2021) · Infection · doi:10.1007/s15010-021-01598-6 · Cited by 55
Hong, S. (2023) · Humanities and Social Sciences Communications · doi:10.1057/s41599-023-01593-2 · Cited by 67
“Vaccination is generally regarded as a critical and cost-effective protective intervention for public health (Polack et al., 2020; Anderson et al., 2020; WHO, 2021a).”
BackgroundGazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben‐Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4130 · Cited by 58
Lee, J. H., & Crotty, S. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101470 · Cited by 61
Precision therapeutic targets for COVID-19
Krumm, Z. A., Lloyd, G. M., Francis, C. P., Nasif, L. H., Mitchell, D. A., Golde, T. E., Giasson, B. I., & Xia, Y. (2021) · Virology Journal · doi:10.1186/s12985-021-01526-y · Cited by 59
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
Shamier, M. C., Tostmann, A., Bogers, S., de Wilde, J., IJpelaar, J., van der Kleij, W. A., de Jager, H., Haagmans, B. L., Molenkamp, R., Oude Munnink, B. B., et al. (2021) · doi:10.1101/2021.08.20.21262158 · Cited by 56
Rearte, A., Castelli, J. M., Rearte, R., Fuentes, N., Pennini, V., Pesce, M., Barbeira, P. B., Iummato, L. E., Laurora, M., Bartolomeu, M. L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00011-3 · Cited by 68
Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.003 · Cited by 62
“3 weeks for BNT162b2), or other factors, such as the lipid composition of the nanoparticles used for packaging the mRNA content [8,9,20].”
BackgroundBeach, M. A., Teo, S. L. Y., Chen, M. Z., Smith, S. A., Pouton, C. W., Johnston, A. P. R., & Such, G. K. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c18359 · Cited by 66
Rosano, G. M. C., Jankowska, E. A., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bayés‐Genís, A., Belenkov, Y. N., Gal, T. B., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2356 · Cited by 64
Syversen, S. W., Jyssum, I., Tveter, A. T., Tran, T. T., Sexton, J., Provan, S. A., Mjaaland, S., Warren, D. J., Kvien, T. K., Grødeland, G., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42153 · Cited by 61
“Age, median years (IQR) 52 (40–63) 57 (46–67) 43 (32–55) Sex Female 899 (55) 80 (52) 854 (77) Male 748 (45) 73 (48) 260 (23) CRP level, median mg/dl (IQR) 1 (1–3) 1 (1–4) No data BMI, median kg/m(2) (IQR) 26 (23–29) 26 (24–29) No data IMID Joint Rheumatoid arthritis 566 (34) 52 (34) NA Psoriatic arthritis 295 (18) 21…”
BackgroundUS authorization of first COVID vaccine marks new phase in safety monitoring
Ledford, H. K. (2020) · Nature · doi:10.1038/d41586-020-03542-4 · Cited by 58
Ye, Z., Yuan, S., Chan, J. F., Zhang, J., Yu, C.-Y., Ong, C. P., Yang, D., Chan, C. C.-Y., Tang, K., Cao, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1885998 · Cited by 53
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 57
“They were not offered the second dose, nor were their outcomes differentiated from the rest of the analysed population [24].”
BackgroundInfluentialGalanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., & Καϊτελίδου, Δ. (2021) · medRxiv · doi:10.1101/2021.07.28.21261261 · Cited by 58
Principles and Challenges in anti-COVID-19 Vaccine Development
Strizova, Z. O., Smetanová, J., Bartůňková, J., & Milota, T. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514225 · Cited by 65
Kim, D. D., Kung, C. S., & Perez, D. L. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1042 · Cited by 54
Khaled, S. M., Petcu, C. G., Bader, L., Amro, I., Al-Hamadi, A. M., Al-Assi, M., Ali, A. A., Trung, K. L., Diop, A., Bellaj, T., et al. (2021) · Vaccines · doi:10.3390/vaccines9050471 · Cited by 62
Chui, C. S. L., Fan, M., Wan, E. Y. F., Leung, M. T. Y., Cheung, E. C. L., Yan, V. K. C., Gao, L., Ghebremichael‐Weldeselassie, Y., Man, K. K. C., Lau, K. K., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101504 · Cited by 62
VILCHES, T. N., Moghadas, S. M., Sah, P., Fitzpatrick, M. C., Shoukat, A., Pandey, A., & Galvani, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42725 · Cited by 55
A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19
Umakanthan, S., Chattu, V. K., Ranade, A. V., Das, D., Basavarajegowda, A., & Bukelo, M. M. (2021) · AIMS Public Health · doi:10.3934/publichealth.2021011 · Cited by 58
Deep learning models for predicting RNA degradation via dual crowdsourcing
Wayment-Steele, H. K., Kladwang, W., Watkins, A. M., Kim, D. S., Tunguz, B., Reade, W., Demkin, M., Romano, J., Wellington-Oguri, R., Nicol, J. J., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00571-8 · Cited by 76
“…based on messenger RNA (mRNA) have shown immense promise as a modular therapeutic platform, allowing potentially any protein to be delivered and translated 1,2 , as evidenced by the rapid deployment of mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3–5 .”
Badraoui, R., Adnan, M., Bardakçi, F., & Alreshidi, M. M. (2021) · Molecules · doi:10.3390/molecules26030673 · Cited by 58
Benda, M. A., Mutschlechner, B., Ulmer, H., Grabher, C., Severgnini, L., Volgger, A., Reimann, P., Lang, T., Atzl, M., Huynh, M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17743 · Cited by 56
“In contrast to haematological patients, a favourable serological response rate of 94 5% can be recorded in patients with solid-organ tumours, which is in line with the general population.(4) These data are supported by the findings of Massarweh et al.”
BackgroundResultInfluentialvan Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100352 · Cited by 57
Emerging SARS-CoV-2 variants: Why, how, and what's next?
Chen, Y. Z., Liu, Q., Zhou, L., Zhou, Y., Yan, H., & Lan, K. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100029 · Cited by 63
Bleicher, I., Kadour‐Peero, E., Sagi‐Dain, L., & Sagi, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.043 · Cited by 58
“Six months later, the developers demonstrated that the vaccine is protective against COVID-19 [6].”
Economic evaluation for mass vaccination against COVID-19
Wang, W., Fann, J. C., Chang, R., Jeng, Y., Hsu, C.-Y., Chen, H.-H., Liu, J., & Yen, A. M. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.020 · Cited by 59
Inhalable nanocatchers for SARS-CoV-2 inhibition
Zhang, H., Zhu, W., Jin, Q., Pan, F., Zhu, J., Liu, Y., Chen, L., Shen, J., Yang, Y., Chen, Q., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102957118 · Cited by 54
Vaccination Prioritization Strategies for COVID-19 in Korea: A Mathematical Modeling Approach
Choi, Y., Kim, J. S., Kim, J. E., Choi, H., & Lee, C. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084240 · Cited by 64
Kang, Y., Sun, C., Sun, J., Xie, C., Zhuang, Z., Xu, H.-Q., Liu, Z., Liu, Y., Peng, S., Yuan, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30222-w · Cited by 60
Fusco, M. D., Moran, M. M., Cane, A. D., Curcio, D., Khan, F. L., Malhotra, D., Surinach, A., Miles, A., Swerdlow, D. L., McLaughlin, J. M., et al. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2002063 · Cited by 57
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 56
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models
Guimarães, L. C., Costa, P. A. C., Scalzo, S., Ferreira, H. A. S., Braga, A. C. S., de Oliveira, L. C., Figueiredo, M. M., Shepherd, S. J., Hamilton, A. G., Queiroz‐Junior, C. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44830-1 · Cited by 65
Pušnik, J., Monzon‐Posadas, W. O., Zorn, J., Peters, K., Baum, M., Proksch, H., Schlüter, C. B., Alter, G., Menting, T., & Streeck, H. (2023) · Nature Communications · doi:10.1038/s41467-023-36250-4 · Cited by 57
The art of prevention: COVID-19 vaccine preparedness for the dermatologist
Rice, S. M., Ferree, S. D., Mesinkovska, N. A., & Kourosh, A. S. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.01.007 · Cited by 56
Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 61
“The first mRNA vaccine, BNT162b2 against SARS-CoV-2, received emergency authorization from the FDA on 11 December 2020, after only 8 months of research, breaking the record for the shortest time needed for vaccine development [17].”
BackgroundA behavioural modelling approach to assess the impact of COVID-19 vaccine hesitancy
Buonomo, B., Marca, R. D., d’Onofrio, A., & Groppi, M. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110973 · Cited by 58
“Before mid December 2020 phase 3 of a number of vaccines ended, showing that they have a very outstanding effectiveness in preventing COVID–19 [2, 52, 64].”
BackgroundAdvanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 56
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 67
Indirect protection of children from SARS-CoV-2 infection through parental vaccination
Hayek, S., Shaham, G., Ben‐Shlomo, Y., Kepten, E., Dagan, N., Nevo, D., Lipsitch, M., Reis, B. Y., Balicer, R. D., & Barda, N. (2022) · Science · doi:10.1126/science.abm3087 · Cited by 53
Role of T cells in severe COVID-19 disease, protection, and long term immunity
Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 60
“In total, severe COVID-19 was observed in 9 placebo subjects and 1 vaccinated subject (Polack et al. 2020) in ~ 120 days after vaccination with Pfizer/BioNTech.”
BackgroundCOVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Iacopetta, D., Ceramella, J., Catalano, A. A., Saturnino, C., PELLEGRINO, M. A., Mariconda, A., Longo, P., Sinicropi, M. S., & Aquaro, S. (2022) · Viruses · doi:10.3390/v14030573 · Cited by 65
Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review
Koike, H., Chiba, A., & Katsuno, M. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00261-4 · Cited by 76
A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19
Logette, E., Lorin, C., Favreau, C., Oshurko, E., Coggan, J. S., Casalegno, F., Sy, M. F., Monney, C., Bertschy, M., Delattre, É., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.695139 · Cited by 63
A flexible, efficient, and scalable platform to produce circular RNAs as new therapeuticsPreprint
Wei, H. Y., Chen, C., Zhang, K., Li, Z., Wei, T., Tang, C., Yang, Y., & Wang, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.31.494115 · Cited by 69
“The circular RNA was encapsulated in a lipid nanoparticle via the NanoAssemblr Ignite system as previously described 30,36 .”
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development
Kim, D.-K., Lai, C., Cha, I., & Jung, J. U. (2024) · Viruses · doi:10.3390/v16010128 · Cited by 64
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
Kitagawa, H., Kaiki, Y., Sugiyama, A., Nagashima, S., Kurisu, A., Nomura, T., Omori, K., Akita, T., Shigemoto, N., Tanaka, J., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.034 · Cited by 56
“The frequency of reported reactions is generally consistent with the results observed in previous studies [3,4,7, 9,10].”
BackgroundResultInfluentialCOVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience
So, A. C. P., McGrath, H., Ting, J., Srikandarajah, K., Germanou, S., Moss, C. L., Russell, B. A., Monroy‐Iglesias, M. J., Dolly, S. O., Irshad, S., et al. (2021) · Cancers · doi:10.3390/cancers13143573 · Cited by 57
Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac392 · Cited by 61
“PCR [2] and/or supplemented with self-reported testing history in online-enrolled participants (see Supplementary Materials).”
BackgroundMethodInfluentialMessenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 63
“While the SARS-CoV-2 mRNA vaccines showed favorable safety profiles across diverse populations, side effects after intramuscular delivery of 30 μg of Pfizer’s mRNA construct, BNT162b2, were mild to moderate, and included pain at the injection site, fatigue, fever, chills, and headache (32, 48).”
Lee, Y. W., Lim, S. Y., Lee, J., Lim, J. S., Kim, M., Kwon, S., Joo, J., Kwak, S. H., Kim, E. O., Jung, J., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e153 · Cited by 55
Modeling the effect of the vaccination campaign on the COVID-19 pandemic
Angeli, M., Neofotistos, G., Mattheakis, M., & Kaxiras, E. (2021) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2021.111621 · Cited by 57
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 56
“CanSino Biologics made a recombinant adenovirus type-5 (Ad5) vector vaccine expressing the S protein, Ad5-nCoV, that was fully immunogenic, and a single dose induced a significant immune response [49,65].”
BackgroundJacobson, K. B., Pinsky, B. A., Montez Rath, M. E., Wang, H., Miller, J. A., Skhiri, M., Shepard, J., Mathew, R., Lee, G., Bohman, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab554 · Cited by 62
“(2-4) In clinical trials, the vaccines demonstrated 52-95% efficacy against symptomatic disease 14 days after the first dose, and 95% efficacy seven days after the second dose.(3, 4) Early observational reports in vaccinated health care personnel suggest 80% effectiveness >14 days after first dose and 90% >14 days aft…”
BackgroundSkawran, S., Gennari, A. G., Dittli, M., Treyer, V., Muehlematter, U. J., Maurer, A. B., Burger, I. A., Mader, C. E., Messerli-Odermatt, O., Grünig, H., et al. (2021) · European Radiology · doi:10.1007/s00330-021-08122-2 · Cited by 55
Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104734 · Cited by 58
Risk, M., Hayek, S. S., Schiopu, E., Yuan, L., Shen, C., Shi, X., Freed, G. L., & Zhao, L. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00216-8 · Cited by 55
Tragni, V., Primiano, G., Tummolo, A., Beltrame, L. C., Piana, G. L., Sgobba, M. N., Cavalluzzi, M. M., Paterno, G., Gorgoglione, R., Volpicella, M., et al. (2022) · Molecules · doi:10.3390/molecules27113494 · Cited by 60
Min, Y. G., Ju, W., Ha, Y.-E., Ban, J., Lee, S., Sung, J., & Shin, J.-Y. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577691 · Cited by 55
“COV2⋅S recipients (Baden et al., 2021; Heath et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021).”
Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Serra, M. G., Kreer, C., et al. (2021) · Viruses · doi:10.3390/v13081498 · Cited by 57
Narayanaswamy, V., Pentecost, B. T., Schoen, C. N., Alfandari, D., Schneider, S. S., Baker, R., & Arcaro, K. F. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004661 · Cited by 60
Lombardi, A., Bozzi, G., Ungaro, R., Villa, S., Castelli, V., Mangioni, D., Muscatello, A., Gori, A., & Bandera, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657711 · Cited by 57
Keshavarz, B., Richards, N. E., Workman, L. J., Patel, J., Muehling, L. M., Canderan, G., Murphy, D. D., Brovero, S. G., Ailsworth, S. M., Eschenbacher, W. H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850987 · Cited by 61
“BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) each use lipid nanoparticles to deliver mRNA that encodes for a pre-fusion stabilized spike glycoprotein immunogen, and both have shown strong protection in clinical trials and real world experience (4, 5).”
BackgroundUwamino, Y., Kurafuji, T., Sato, Y., Tomita, Y., Shibata, A., Tanabe, A., Yatabe, Y., Noguchi, M., Arai, T., Ohno, A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.002 · Cited by 56
“The Pfizer-BioNTech BNT162b2 mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine is one of the newly developed SARS-CoV-2 vaccines using the messenger RNA coding spike protein of SARS-CoV-2 and has demonstrated dramatic efficacy in clinical trials [1,2] and the real-world [3,4].”
BackgroundBolze, A., Neveux, I., Barrett, K. M. S., White, S. J., Isaksson, M., Dabe, S., Lee, W., Grzymski, J. J., Washington, N. L., & Cirulli, E. T. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100084 · Cited by 63
“Our results were in agreement with what was previously reported.(2,3,14) For the Pfizer-BioNTech vaccine, we observed that only 2.”
Revolutionising health care: Exploring the latest advances in medical sciences
Mahara, G., Tian, C., Xu, X., & Wang, W. (2023) · Journal of Global Health · doi:10.7189/jogh.13.03042 · Cited by 77
Breathnach, A. S., Riley, P. A., Cotter, M., Houston, A., Habibi, M. S., & Planche, T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.005 · Cited by 57
Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents
Bardenheier, B. H., Gravenstein, S., Blackman, C., Gutman, R., Sarkar, I. N., Feifer, R. A., White, E. M., McConeghy, K. W., Nanda, A., & Mor, V. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.088 · Cited by 56
“However, both the Pfizer-BioNTech and Moderna vaccine trials excluded NH residents [3,4].”
BackgroundLeong, C., Jin, L. J., Kim, D., Kim, J., Teo, Y. Y., & Ho, T. (2022) · Communications Medicine · doi:10.1038/s43856-022-00123-6 · Cited by 55
“001); (2) vaccines are “effective” was 0.”
RetractedKiem, C. T., Massonnaud, C., Lévy-Bruhl, D., Poletto, C., Colizza, V., Bosetti, P., Fontanet, A. L., Gabet, A., Olié, V., Zanetti, L. C. D. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101001 · Cited by 61
COVID-19 vaccines: implementation, limitations and opportunities
Richman, D. D. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01010 · Cited by 55
mRNA lipid nanoparticle formulation, characterization and evaluation
Ma, Y., VanKeulen-Miller, R., & Fenton, O. S. (2025) · Nature Protocols · doi:10.1038/s41596-024-01134-4 · Cited by 54
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
Dietz, L. L., Juhl, A. K., Søgaard, O. S., Reekie, J., Nielsen, H., Johansen, I. S., Benfield, T., Wiese, L., Stærke, N. B., Jensen, T. Ø., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00277-x · Cited by 56
Ekizoğlu, E., Gezegen, H., Dikmen, P. Y., Orhan, E. K., Ertaş, M., & Baykan, B. B. (2021) · Cephalalgia · doi:10.1177/03331024211042390 · Cited by 55
“Moreover, patients with headache related to COVID-19 and mRNA COVID-19 vaccine were also found to be younger in comparison to those without headache (9,28).”
ResultCOVID-19 vaccination in our transplant recipients: The time is now
Aslam, S., Goldstein, D. R., Vos, R., Gelman, A. E., Kittleson, M. M., Wolfe, C. R., & Danziger‐Isakov, L. A. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.12.009 · Cited by 56
Lapointe, H. R., Mwimanzi, F. M., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Speckmaier, S., Moran-Garcia, N., Datwani, S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac229 · Cited by 75
“Although 2-dose COVID-19 vaccination protects against severe disease [5–7], impaired responses have been observed in certain immunocompromised groups [8 –12 ], prompting research into COVID-19 vaccine responses in PLWH.”
Yazaki, S., Yoshida, T., Kojima, Y., Yagishita, S., Nakahama, H., Okinaka, K., Matsushita, H., Shiotsuka, M., Kobayashi, O., Iwata, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2159 · Cited by 56
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.